These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 15538248)

  • 1. Cost-effectiveness of medical management strategies for nephrolithiasis.
    Lotan Y; Cadeddu JA; Roerhborn CG; Pak CY; Pearle MS
    J Urol; 2004 Dec; 172(6 Pt 1):2275-81. PubMed ID: 15538248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. International comparison of cost effectiveness of medical management strategies for nephrolithiasis.
    Lotan Y; Cadeddu JA; Pearle MS
    Urol Res; 2005 Jun; 33(3):223-30. PubMed ID: 15924256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urolithiasis: Update on Metabolic Evaluation of Stone Formers.
    Park S; Pearle MS
    ScientificWorldJournal; 2005; 5():902-914. PubMed ID: 29861685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. When is medical prophylaxis cost-effective for recurrent calcium stones?
    Chandhoke PS
    J Urol; 2002 Sep; 168(3):937-40. PubMed ID: 12187194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary prevention of nephrolithiasis is cost-effective for a national healthcare system.
    Lotan Y; Buendia Jiménez I; Lenoir-Wijnkoop I; Daudon M; Molinier L; Tack I; Nuijten MJ
    BJU Int; 2012 Dec; 110(11 Pt C):E1060-7. PubMed ID: 22686216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of socioeconomic status in etiology and management of urinary stone disease.
    Ansari MS; Gupta NP
    Urol Int; 2003; 70(4):255-61. PubMed ID: 12776701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economics of stone management.
    Lotan Y; Pearle MS
    Urol Clin North Am; 2007 Aug; 34(3):443-53. PubMed ID: 17678993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group.
    Prezioso D; Strazzullo P; Lotti T; Bianchi G; Borghi L; Caione P; Carini M; Caudarella R; Ferraro M; Gambaro G; Gelosa M; Guttilla A; Illiano E; Martino M; Meschi T; Messa P; Miano R; Napodano G; Nouvenne A; Rendina D; Rocco F; Rosa M; Sanseverino R; Salerno A; Spatafora S; Tasca A; Ticinesi A; Travaglini F; Trinchieri A; Vespasiani G; Zattoni F;
    Arch Ital Urol Androl; 2015 Jul; 87(2):105-20. PubMed ID: 26150027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines.
    Skolarikos A; Straub M; Knoll T; Sarica K; Seitz C; Petřík A; Türk C
    Eur Urol; 2015 Apr; 67(4):750-63. PubMed ID: 25454613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Socioeconomic aspects of urinary calculi and metaphylaxis of urinary calculi].
    Strohmaier WL
    Urologe A; 2000 Mar; 39(2):166-70. PubMed ID: 10768228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation and medical management of kidney stones in children.
    Tasian GE; Copelovitch L
    J Urol; 2014 Nov; 192(5):1329-36. PubMed ID: 24960469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Economic aspects of evidence-based metaphylaxis].
    Strohmaier WL
    Urologe A; 2006 Nov; 45(11):1406-9. PubMed ID: 17063349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Urinary stone management at the time of its discovery].
    Conort P; Tostivint I
    Rev Prat; 2011 Mar; 61(3):379-81. PubMed ID: 21563418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pathophysiology, diagnosis and conservative therapy in calcium kidney calculi].
    Hess B
    Ther Umsch; 2003 Feb; 60(2):79-87. PubMed ID: 12649986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced renal function and benefits of treatment in cystinuria vs other forms of nephrolithiasis.
    Worcester EM; Coe FL; Evan AP; Parks JH
    BJU Int; 2006 Jun; 97(6):1285-90. PubMed ID: 16686727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial Results from the M-STONE Group: A Multi-Center Collaboration to Study Treatment Outcomes in Nephrolithiasis Evaluation.
    Johnson BA; Best SL; Nakada SY; Tracy C; Steinberg RL; Thomas L; Marien T; Miller N; Kolitz E; Cohen A; Pearle MS; Lotan Y; Antonelli JA
    J Endourol; 2020 Sep; 34(9):919-923. PubMed ID: 32660266
    [No Abstract]   [Full Text] [Related]  

  • 17. Economics and cost of care of stone disease.
    Lotan Y
    Adv Chronic Kidney Dis; 2009 Jan; 16(1):5-10. PubMed ID: 19095200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic risk factors and the impact of medical therapy on the management of nephrolithiasis in obese patients.
    Ekeruo WO; Tan YH; Young MD; Dahm P; Maloney ME; Mathias BJ; Albala DM; Preminger GM
    J Urol; 2004 Jul; 172(1):159-63. PubMed ID: 15201761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical management of kidney stones: AUA guideline.
    Pearle MS; Goldfarb DS; Assimos DG; Curhan G; Denu-Ciocca CJ; Matlaga BR; Monga M; Penniston KL; Preminger GM; Turk TM; White JR;
    J Urol; 2014 Aug; 192(2):316-24. PubMed ID: 24857648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Course of calcium stone disease without treatment. What can we expect?
    Strohmaier WL
    Eur Urol; 2000 Mar; 37(3):339-44. PubMed ID: 10720863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.